Announcements Trials
Browse Landscape

Phase

Phase 1 3Phase 1/2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Leukemia 3Myelodysplastic Syndromes 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma 1Leukemia, Myeloid, Acute 1Leukemia, Lymphocytic, Chronic, B-Cell 1Hodgkin Disease 1Congenital Abnormalities 1

Interventions

Cyclophosphamide 18fludarabine phosphate 16Rituximab 16Etoposide 16Peripheral Blood Stem Cell Transplantation 14Brentuximab Vedotin 14fludarabine 11Whole-Body Irradiation 11Nivolumab 11Mycophenolic Acid 11Bendamustine Hydrochloride 11Tacrolimus 10Melphalan 10Filgrastim 9Gemcitabine 8Carboplatin 8Ifosfamide 7Cytarabine 7Cyclosporine 7Busulfan 7pembrolizumab 6Lenalidomide 6Doxorubicin 6Prednisone 5Everolimus 5Antilymphocyte Serum 5Alemtuzumab 5Vinblastine 4Methotrexate 4Mesna 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Hodgkin Disease × laromustine × Clear all
NCT00304005 2013-07-18

VNP40101M in Treating Patients With Richter Syndrome or Refractory or Relapsed Chronic Lymphocytic Leukemia or Other Lymphoproliferative Disorders

National Cancer Institute (NCI)

Phase 1/2 Completed
35 enrolled
LymphoidOther hematologic neoplasm

Hodgkin Disease, Leukemia, Lymphoma, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Large B-Cell, Diffuse

Data powered by HemOnc (CC BY 4.0) Colophon âš¡